Efficacy of postoperative antiviral combined transcatheter arterial chemoembolization therapy in prevention of hepatitis B-related hepatocellular carcinoma recurrence

被引:0
|
作者
YAN Qiang [1 ,2 ]
NI Jun [2 ]
ZHANG Guo-lei [2 ]
YAO Xing [2 ]
YUAN Wen-bin [2 ]
ZHOU Lin [1 ]
ZHENG Shu-sen [1 ]
机构
[1] Division of Hepatobiliary and Pancreatic Surgery,First Affiliated Hospital,Zhejiang University School of Medicine
[2] Department of Hepatobiliary and Pancreatic Surgery,Huzhou Central Hospital
关键词
D O I
暂无
中图分类号
R735.7 [肝肿瘤];
学科分类号
100214 ;
摘要
Background Recurrence of hepatitis B-related hepatocellular carcinoma(HCC) after curative resection is the leading factor influencing the prognosis of the disease.Therefore,further improvement of long-term survival may depend on the prevention and treatment of the recurrent tumor.The aim of this research was to investigate the role of antiviral therapy and postoperative transcatheter arterial chemoembolization(TACE) in the prevention and treatment of hepatitis B-related HCC recurrence.Methods One hundred and twenty patients who underwent curative resection of hepatitis B-related HCC between January 2005 and June 2008 at our hospital were enrolled.Patients were divided into four groups according to the post-operative adjuvant therapy they received,i.e.,control,antiviral therapy group,TACE group,and combined group.The disease-free survival(DFS) and the 12-,24-,36-month cumulative recurrence rates were studied.Results There was no significant difference between isolated postoperative antiviral therapy group and control in terms of disease-free survival(P=0.283),while it was significantly higher in the TACE group compared to control(P=0.019).In all patients,however,viral prophylactic therapy combined with/without TACE brought a favorable result compared to those only with/without TACE(P <0.001).Similarly,no matter combined with or without antiviral treatment,postoperative TACE prolonged DFS(P=0.015).Naturally,a combination of viral prophylactic therapy on the baseline TACE significantly benefited patients’ postoperative DFS(P=0.047) and vice verse(P=0.002).The 24-month cumulative recurrence rates of combined group were significantly lower than that of isolated control group and antiviral therapy(P<0.001 and P=0.011respectively).However,36-month recurrence rate was significantly different in the control group compared to the TACE group and combined group(P=0.040 and 0.002 respectively);same as the antiviral group compared to the combined group(P=0.034).Conclusions Post-operative TACE prevents early recurrence while antiviral therapy prevents late recurrence of HCC.Combination of antiviral therapy and TACE are suggested for prevention in HCC patients with high risk of recurrence.
引用
收藏
页码:855 / 859
相关论文
共 50 条
  • [1] Efficacy of postoperative antiviral combined transcatheter arterial chemoembolization therapy in prevention of hepatitis B-related hepatocellular carcinoma recurrence
    Yan Qiang
    Ni Jun
    Zhang Guo-lei
    Yao Xing
    Yuan Wen-bin
    Zhou Lin
    Zheng Shu-sen
    CHINESE MEDICAL JOURNAL, 2013, 126 (05) : 855 - 859
  • [2] Analysis of factors affecting the prognosis of transcatheter arterial chemoembolization for hepatitis B-related hepatocellular carcinoma
    Jiangping Cun
    Yonghui Xu
    Weidong Li
    Xingxiang Zhao
    Journal of Interventional Medicine, 2021, (02) : 66 - 70
  • [3] Antiviral therapy, HBsAg seroclearance and late recurrence of hepatitis B-related hepatocellular carcinoma
    Liu, Si-Yu
    Yuan, Chen
    Tong, Xiang-Min
    JOURNAL OF HEPATOLOGY, 2022, 77 (05) : 1471 - 1472
  • [4] Perioperative antiviral therapy for chronic hepatitis B-related hepatocellular carcinoma
    Qiang Wei
    Xiao Xu
    Qi Ling
    Bo Zhou
    Shu-Sen Zheng
    Hepatobiliary&PancreaticDiseasesInternational, 2013, 12 (03) : 251 - 255
  • [5] Comparative efficacy of postoperative transarterial chemoembolization with or without antiviral therapy for hepatitis B virus-related hepatocellular carcinoma
    Zhu, Shao-Liang
    Zhong, Jian-Hong
    Ke, Yang
    Xiao, Hui-Min
    Ma, Liang
    Chen, Jie
    You, Xue-Mei
    Li, Le-Qun
    TUMOR BIOLOGY, 2015, 36 (08) : 6277 - 6284
  • [6] Perioperative antiviral therapy for chronic hepatitis B-related hepatocellular carcinoma
    Wei, Qiang
    Xu, Xiao
    Ling, Qi
    Zhou, Bo
    Zheng, Shu-Sen
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2013, 12 (03) : 251 - 255
  • [7] POSTOPERATIVE RECURRENCE OF HEPATOCELLULAR-CARCINOMA - RESULTS OF TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION
    PARK, JH
    HAN, JK
    CHUNG, JW
    HAN, MC
    KIM, ST
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 1993, 16 (01) : 21 - 24
  • [8] the prevention of hepatitis B-related hepatocellular carcinoma
    Lin, C. -L.
    Kao, J. -H.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 48 (01) : 5 - 14
  • [9] Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma
    Liu, Chen
    Sun, Li
    Xu, Jingchao
    Zhao, Yongfu
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2016, 14
  • [10] Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma
    Chen Liu
    Li Sun
    Jingchao Xu
    Yongfu Zhao
    World Journal of Surgical Oncology, 14